← FDA Drug Approvals (Drugs@FDA)

CABAZITAXEL

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: ACCORD HLTHCARE · Approved 2022-10-26

Drug application

FDA Application #

ANDA207693

Application type

Abbreviated New Drug Application (Generic)

Brand name

CABAZITAXEL

Generic name

Cabazitaxel

Active ingredients

CABAZITAXEL

Dosage form

SOLUTION

Route

INTRAVENOUS

Marketing status

Prescription

Sponsor

ACCORD HLTHCARE

First approval

2022-10-26

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown